|
Getting your Trinity Audio player ready...
|
In recent times Halberd Corporation (OTC:HALB) is a healthcare company that has made considerable progress in its research and development activities. As a consequence, the company has garnered significant attention from investors as well.
Trading Data
On Tuesday, HALB stock went down 6.57% to $0.0093 with more than 184K shares, compared to a volume of 1.48 million shares. The stock moved within a range of $0.0087 – 0.0098 after opening trade at $0.0098.
This morning the company is back in the news once again after it made another major announcement with regard to its latest breakthrough. The company announced this morning that it had been successful in removing Interleukin-6 (IL-6) from the human blood serum during the course of in-vitro laboratory testing. It was a major new announcement from Halberd Corporation considering the fact that Interleukin-6 is known for causing a wide range of difficult health conditions in human beings.
In this regard, it is also necessary to point out that in the case of the latest studies the company had actually used a different methodology. In the past, the company had been successful in the removal of IL-6 from cerebrospinal fluid by way of laser radiation exposure.
However, in the latest study, the company had actually used an engineered antibody that is well known for having a strong binding affinity to IL-6. It goes without saying that it was a major new development for the company and one that is expected to burnish its credentials as a company with serious research and development credentials.
William A Hartman, who is the Chief Executive Officer, Chairman, and President of the company spoke about the company’s working style as well. He noted that in recent times many have stated that the company’s method of working was a bit ‘all over the place’ but Hartman stated that it was an inaccurate representation of its work.
The company has managed to make a considerable breakthrough in coming up with research and development for tackling a range of diseases. Instead, Halberd Corporation had a platform that allowed the company to work on a range of projects due to its universal applicability.
Technical Data
HALB stock is trading below the 20-Day and 50-Day Moving averages of $0.0099 and $0.0109 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0166.
Related posts:
Human Unitec International, Inc. (OTCMKTS:HMNU) Announces Medical Equipment Deal in China Closed Up 17.78% 10x Volume: RSHN, ALST, HALB, EPAZ
Halberd Corporation (OTCMKTS:HALB) Stock Moves Back Above 50-Day MA on Big News
Pennies @ 52-Week Lows Time to Buy: ZRFY, HALB, MMMW, ALST, HMNU, CEOS
2023 Medical Stocks to Watch Under 1¢ Now! HALB, GRST, HMNU
Halberd (OTC:HALB) Eradicates 99.5% of CDC Provided Antibiotic Resistant Bacteria